Comparison of single agent cisplatin and cisplatin containing combinations in treatment of murine bladder cancer

David P. Hickey, Maurizio Brausi, Anthony F. Blatnik, Mark S. Soloway

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

Using the FANFT-induced tumors MBT-2 and MBT-683 we compared the response rate and survival using cisplatin alone and in various combinations with doxorubicin hydrochloride (Adriamycin), mitomycin C, methotrexate, and vinblastine. Sixty C3H/He female mice received 7.5 × 104 MBT-2 cells in the right hind limb. The animals were randomly divided into a control group and four treatment groups as follows: cisplatin, 6.0 mg/kg; cisplatin, 2.0 mg/kg, vinblastine, and methotrexate; cisplatin, 2.0 mg/kg, vinblastine, methotrexate, and doxorubicin hydrochloride; and cisplatin, 2.0 mg/kg, vinblastine, methotrexate, and mitomycin C. The drugs were given intraperitoneally on days 7, 14, and 21. The study was repeated using MBT-683. Drug effect on tumor diameter and survival were compared. Cisplatin alone was as effective in MBT-2 and more effective in MBT-683 in reducing tumor volume and increasing survival than the various combinations. The higher tolerable dose of cisplatin used as a single agent probably accounts for these results and suggests that cisplatin is the most effective agent in these combination therapy regimens.

Original languageEnglish (US)
Pages (from-to)484-487
Number of pages4
JournalUrology
Volume30
Issue number5
DOIs
StatePublished - Nov 1987

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Comparison of single agent cisplatin and cisplatin containing combinations in treatment of murine bladder cancer'. Together they form a unique fingerprint.

  • Cite this